Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) chief scientific officer Dr Mark Bleackley tells Proactive they have completed the dosing stage in a Phase 1 anti-inflammatory drug trial. The clinical-stage pharmaceutical company is now readying for Phase 2 clinical trials in patients with rheumatoid arthritis. Down the line, the company will also study the impact in participants with inflammatory bowel disease and lung inflammation.
Incannex Healthcare plans Phase 2 studies for anti-inflammatory drug
